Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination
Journal of Infection and Chemotherapy
; 29(1):105-108, 2023.
Article
in English
| Scopus | ID: covidwho-2244816
ABSTRACT
Acute exacerbations due to COVID-19 vaccination in patients with interstitial lung disease (ILD) have been reported, but their incidence is unknown. We investigated the incidence of exacerbations of ILD and respiratory symptoms due to the mRNA COVID-19 vaccines. A questionnaire survey was conducted on adverse reactions to the mRNA COVID-19 vaccination in 545 patients with ILD attending our hospital and retrospectively examined whether the eligible patients actually developed acute exacerbations of ILD induced by the vaccine. Of the 545 patients, 17 (3.1%) patients were aware of the exacerbation of respiratory symptoms, and four (0.7%) patients developed an acute ILD exacerbation after vaccination. Of the four patients who experienced exacerbations, two had collagen vascular disease-associated ILD, one had nonspecific interstitial pneumonia, another had unclassifiable idiopathic pneumonia, and none had idiopathic pulmonary fibrosis. Four patients were treated using steroid pulse therapy with a steroid taper, and two of the four also received intravenous cyclophosphamide pulse therapy. Tacrolimus was started in one patient with myositis-associated interstitial lung disease. Eventually, all patients exhibited improvement with immunosuppressive treatment and were discharged. COVID-19 vaccination for patients with ILD should be noted for developing acute exacerbations of ILD with low incidence, although manageable with early diagnosis and treatment. © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
COVID-19; COVID-19 Vaccines; Disease Progression; Humans; Incidence; Lung Diseases, Interstitial; Retrospective Studies; RNA, Messenger; Vaccination; cyclophosphamide; elasomeran; nintedanib; pirfenidone; SARS-CoV-2 vaccine; steroid; tacrolimus; tozinameran; messenger RNA; aged; arthralgia; Article; chill; collagen vascular disease; coronavirus disease 2019; diarrhea; disease exacerbation; fatigue; female; fever; headache; human; immunosuppressive treatment; interstitial lung disease; interstitial pneumonia; major clinical study; male; myalgia; myositis; nausea; pneumonia; questionnaire; rash; retrospective study; side effect; adverse event; prevention and control; Acute exacerbation; SARS-CoV-2; Vaccine
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Type of study:
Observational study
Topics:
Vaccines
Language:
English
Journal:
Journal of Infection and Chemotherapy
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS